CROME ICDs and CRT-Ds

Crome™ ICDs and CRT-Ds with BlueSync™ technology enable tablet-based programming and app-based remote monitoring, and provide proven exclusive shock reduction algorithms. 

Download Brochure

Overview

the  future is here

Meet Crome ICDs and CRT-Ds

With tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.

UNMATCHED FEATURE SUITE 

Extended Longevity

Mean longevity projections based on CareLink™ patient data.*

Graph depicting Crome's longevity projections against Claria and Amplia MRI devices
Graph depicting Crome Dual Chamber's longevity projections against Evera and Evera MRI Dual Chamber ICDs
Graph depicting Crome Single Chamber's longevity projections against Visia AF and Visia AF MRI Single Chamber

Increased Energy Delivery

Option for 40 J energy delivery on all shocks, including the first.

MAXIMUM PROGRAMMED ENERGY 40 J

MAXIMUM

DELIVERED

ENERGY<sup>†</sup>

40 J

MAXIMUM

STORED

ENERGY<sup>‡</sup>

47 J

Exclusive Algorithms to Manage AF 

DETECT AF

Dual Chamber and CRT-D

  • Highest published detection accuracy of 95-96% episode PPV.§||7-10

AF Episode Detection Accuracy (PPV)§||7

Graph depicting AF detection accuracy in multiple devices

REDUCE AF

CRT-D

  • Reactive ATP™ algorithm opportunistically attempts to terminate an AF episode when the rhythm organizes and/or slows. 
  • 36% relative reduction in AT/AF episodes ≥ 7 days with Reactive ATP algorithm.¶13
Crome HF Quad CRT-D Device on a white background

REIMAGINED CONNECTIVITY 

BlueSync Technology

BlueSync technology within Crome enables secure, wireless communication.

CareLink SmartSync interface shown on tablet

Tablet-based CareLink SmartSync™ device manager

Image showing Crome ICDs and CRT-Ds

Crome ICDs and CRT-Ds

Image of app and home communicator on white background

MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator

BeConnected service shown on desktop monitor

CareLink network and the
Get Connected service

STREAMLINED WORKFLOWS

Additional CAREALERT NOTIFICATIONS

Manage alerts of clinically relevant events with additional CareAlert™ notifications.

Tachyarrhythmia Status:

  • Monitored VT
  • Weekly ATP delivered
  • Daily VT/VF episodes

Bradyarrhythmia Status:

  • Right ventricular pacing > 40%
  • High capture thresholds

Heart Failure Status:

  • Ventricular pacing < 90%
  • OptiVol™ 2.0 Fluid Status Monitoring (CRT-D)

System features & Exclusive Algorithms

Discover exclusive features and algorithms available in Crome ICDs and CRT-Ds.

Model Specifications

Additional resources 

Medtronic 24-hour support

1-800-505-4636

Medtronic Academy

Find additional feature information along with a variety of educational resources and tools.

Visit Medtronic Academy
*

These values should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.

Energy delivered at connector block into a 50 Ω ± 1% load.

Energy stored at charge end on capacitor.

§

A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. AF detection accuracy rates determined from independent clinical trials are presented for reference.

||

Detection accuracy is compared using PPV, which is the percentage of all AT/AF episodes detected by the individual device detection algorithm that were adjudicated as true AT/AF.

Compared to matched control group.

References

1

Medtronic Compia MRI™ CRT-D, Amplia MRI™ CRT-D, and Claria MRI™ CRT-D Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236  EN.

2

Medtronic Crome™ HF Quad MRI SureScan™ Model DTPC2QQ device manual.

3

Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236  EN.

4

Medtronic Crome™ DR MRI SureScan™ Model DDPC3D4 device manual.

5

Medtronic Visia AF™ VR Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236  EN.

6

Medtronic Crome™ VR ICD MRI SureScan™ Model DVPC3D4 device manual.

7

Sprenger M. Comparison of Manufacturer’s AT/AF Detection Accuracy across Clinical Studies. January 2015. Medtronic data on file.

8

Pürerfellner H, Gillis AM, Holbrook, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol. July 2004;27(7):983-992.

9

Ziegler PD, et al. Accuracy of Atrial Fibrillation Detection in Implantable Pacemakers. Presented at HRS 2013 (PO02-08); Denver, CO.

10

Medtronic data on file. QADoc DSN026170, Version 2.0, “AT/AF Duration Performance Comparison.”

11

Kauffman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm. August 2012;9(8):1241-1246.

12

Nowak B, McMeekin J, Knops M, et al. Validation of dual-chamber pacemaker diagnostic data using dual-channel stored electrograms. Pacing Clin Electrophysiol. July 2005;28(7):620-629.

13

Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. July 2019;42(7):970-979.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.